Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.480
+0.010 (0.22%)
At close: May 15, 2026, 4:00 PM EDT
4.560
+0.080 (1.79%)
After-hours: May 15, 2026, 6:59 PM EDT

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
16.7212.147---
Revenue Growth (YoY)
138.86%73.43%----
Gross Profit
16.7212.147---
Selling, General & Admin
21.7722.4128.7228.8830.6526.96
Research & Development
79.0994.3118103.3992.8986.78
Total Operating Expenses
100.86116.71146.71132.28123.54113.74
Operating Income
-84.14-104.57-139.71-132.28-123.54-113.74
Total Non-Operating Income (Expense)
6.345.0712.5410.458.12.04
Pretax Income
-77.8-99.5-127.17-121.83-115.44-111.69
Net Income
-77.8-99.5-127.17-121.83-115.44-111.69
Net Income to Common
-77.8-99.5-127.17-121.83-115.44-111.69
Shares Outstanding (Basic)
797776604746
Shares Outstanding (Diluted)
797776604746
Shares Change (YoY)
3.59%1.52%25.60%27.41%2.87%269.03%
EPS (Basic)
-1.00-1.29-1.68-2.02-2.44-2.43
EPS (Diluted)
-1.00-1.29-1.68-2.02-2.44-2.43
Shares Outstanding
14.7362.9555.1554.9147.947.6
Free Cash Flow
-43.78-56.37-103.65-110.58-86.75-85.85
Free Cash Flow Per Share
-0.56-0.73-1.37-1.83-1.83-1.86
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-503.21%-861.33%-1995.91%---
Profit Margin
-465.30%-819.59%-1816.76%---
FCF Margin
-261.82%-464.32%-1480.74%---
EBITDA
-82.47-102.86-137.94-131.11-122.22-112.82
EBITDA Margin
-493.24%-847.24%-1970.60%---
EBIT
-84.14-104.57-139.71-132.28-123.54-113.74
EBIT Margin
-503.21%-861.33%-1995.91%---
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q